 |
|
|
| |
ALT levels and risk of hepatocellular carcinoma in Caucasian chronic hepatitis B (CHB) patients under long-term therapy
with entecavir or tenofovir disoproxil fumarate
|
| |
| |
Reported by Jules Levin
AASLD 2018 Nov 9-13 SF
G Papatheodoridis1, G Dalekos2, C Yurdaydin3, V Sypsa4, F Van Boemmel5,
M Buti6, JL Calleja7, H Chi8, J Goulis9, S Manolakopoulos1,10, A Loglio11,
S Siakavellas1, N Gatselis2, O Keskin3, R Veelken5, M Lopez-Gomez7,
BE Hansen8,12, S Savvidou9, A Kourikou10, J Vlachogiannakos1, K Galanis2,
R idilman3, R Esteban6, HLA Janssen12, T Berg5, P Lampertico11.
1Dept. of Gastroenterology, National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece; 2Dept. of internal Medicine, Thessalia University Medical School, Larissa, Greece; 3Dept. of Gastroenterology, University of Ankara Medical School, Ankara, Turkey; 4Dept. of Hygiene, Epidemiology & Medical Statistics, Athens University Medical School, Athens, Greece; 5Section of Hepatology, University Clinic Leipzig, Germany; 6Hospital General Universitario Valle Hebron and Ciberehd, Barcelona, Spain; 7Hospital U Puerta de Hierro, iDiPHiM CiBERehd, Madrid, Spain; 8Dept. of Gastroenterology & Hepatology, ErasmusMC, Rotterdam, Netherlands; 94th Dept. of internal Medicine, Aristotle University of Thessaloniki Medical School, Thessaloniki, Greece; 102nd Dept. of internal Medicine, Athens University Medical School, Athens, Greece; 111st Division of Gastroenterology, Fondazione iRCCS Cą Granda Ospedale Maggiore Policlinico, Universitą degli Studi di Milano, Milano, italy; 12Liver Clinic, Toronto Western & General Hospital, University Health Network, Toronto, ON, Canada.
|
| |
|
|
|
|
|
